Pulmonary NEC (130/166, 78.3%; p < 0.001) showed a significantly increased rate of general DLL3 expression compared to GEP-NEC (58/133, 43.6%; p < 0.001), and also, the rate of strongly positive cases (pulmonary NEC: 92/166, 55.4% vs. GEP-NEC: 34/133, 25.6%; p < 0.001) was significantly enriched in pulmonary NEC (Fig. 1F). The gene discussed is DLL3; the disease is neuroendocrine carcinoma.